

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 2006		2. REPORT TYPE Open Literature		3. DATES COVERED (From - To)	
4. TITLE AND SUBTITLE Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds?				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Maxwell, DM, Brecht, KM, Koplovitz, I, Sweeney, RE				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDR-P 3100 Ricketts Point Road				8. PERFORMING ORGANIZATION REPORT NUMBER USAMRICD-P06-012	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research Institute of Chemical Defense ATTN: MCMR-CDZ-P 3100 Ricketts Point Road				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES Published in Archives of Toxicology, 80, 756-760, 2006.					
14. ABSTRACT See reprint.					
15. SUBJECT TERMS oxime reactivation, organophosphorus, acetylcholinesterase inhibition, dose-response, toxic mechanism					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UNLIMITED	18. NUMBER OF PAGES 5	19a. NAME OF RESPONSIBLE PERSON Donald M. Maxwell
a. REPORT UNLIMITED	b. ABSTRACT UNLIMITED	c. THIS PAGE UNLIMITED			19b. TELEPHONE NUMBER (include area code) 410-436-1315

Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds?

Donald M. Maxwell · Karen M. Brecht ·
Irwin Koplovitz · Richard E. Sweeney

Received: 10 April 2006 / Accepted: 11 May 2006 / Published online: 13 June 2006
© Springer-Verlag 2006

Abstract The hypothesis that acetylcholinesterase (AChE) inhibition is the mechanism of toxicity of organophosphorus (OP) compounds was examined by mathematically modeling the *in vivo* lethal effects of OP compounds and determining the amount of variation in OP toxicity that is explained by AChE inhibition. Mortality dose–response curves for several OP compounds (i.e., VX, soman, cyclosarin, sarin, tabun, diisopropylfluorophosphate and paraoxon) exhibited steep probit slopes (> 9.6) in guinea pigs. Steep probit slopes were also observed when the mortality dose–response curves for soman were examined in mice, rats, rabbits and non-human primates. The consistently steep probit slopes of the dose–response curves for highly toxic OP compounds suggested that these compounds have a single specific mechanism of toxicity regardless of the OP compound or the species in which it was tested. Regression analysis indicated that 93% of the 3,280-fold variation in the median lethal doses (i.e., LD_{50}) of OP compounds in rats was explained by the variation in their *in vitro* rate constants for inhibition of AChE. Conversely, 91% of the 23-fold variation in the ability of the oximes pralidoxime and obidoxime to protect against the toxicity of OP compounds in guinea pigs was explained by the variation in the *in vitro* ability of oximes to reactivate OP-inhibited AChE. The best explanation for this variety of observations was that the primary mechanism of *in vivo* toxicity for

highly toxic OP compounds is the inhibition of AChE, and the residual unexplained variation in OP toxicity that might be explained by other mechanisms represents $< 10\%$ of the total variation in OP toxicity.

Keywords Organophosphorus · Acetylcholinesterase inhibition · Oxime reactivation · Dose–response · Toxic mechanism

Introduction

Although the *in vitro* effect of organophosphorus (OP) compounds on acetylcholinesterase (AChE) has been extensively studied (De Jong and Benschop 1988), the hypothesis that OP inhibition of AChE is the primary mechanism of acute *in vivo* OP toxicity has recently undergone re-examination. The acute toxicity of OP compounds has traditionally been attributed to inhibition of AChE because the pathophysiological effects of these compounds (e.g., bradycardia, increased tracheobronchial secretions, bronchoconstriction, seizures and respiratory depression) are consistent with a cholinergic mechanism of toxicity (Karczmar 1970; Marrs 1993; Taylor 2001). However, several recent papers have suggested that OP compounds have direct toxic effects on other enzymes, acetylcholine receptors and receptor/channel complexes that are independent of AChE inhibition (Sultatos 1994; Pope 1999; Schuh et al. 2002; Pope and Liu 2004; Casida and Quistad 2005). A possible reason for the departure of these proposed mechanisms from the traditional mechanism of OP toxicity may be that low toxicity OP compounds can react with more sites of toxicity because of the high doses of these compounds required to produce toxic

D. M. Maxwell (✉) · K. M. Brecht · I. Koplovitz ·
R. E. Sweeney
US Army Medical Research Institute of Chemical Defense,
3100 Ricketts Point Road, Aberdeen Proving Ground,
MD 21010-5400, USA
e-mail: donald.maxwell@amedd.army.mil

effects in comparison to high toxicity OP compounds for which a single specific site of toxicity is more plausible. The purpose of this report is to examine the hypothesis that AChE inhibition is the mechanism of acute toxicity of OP compounds by mathematically modeling the in vivo lethal effects of highly toxic OP compounds and determining the amount of variation in OP toxicity that is explained by AChE inhibition.

Materials and methods

Animals

Male Sprague–Dawley rats (230–250 g), Hartley guinea pigs (330–360 g), New Zealand rabbits (2.5–3.0 g) and CD-1 (ICR) mice (22–26 g) were obtained from Charles River Laboratories (Wilmington, MA), quarantined upon arrival and screened for evidence of disease. Animals were allowed free access to food and water before and after administration of organophosphorus (OP) compounds or drugs. Animal rooms were maintained at 20–22°C and 50% relative humidity with at least ten complete air changes per hour. All animals were on a 12-h light/dark full spectrum lighting cycle with no twilight. All animal procedures described in this report were performed in accordance with the Guide for the Care and Use of Laboratory Animals by the Institute of Laboratory Animal Resources, National Research Council, in accordance with the stipulations mandated for an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility.

Chemicals

Soman, sarin, VX, cyclosarin and tabun were obtained from the Edgewood Chemical and Biological Center (Aberdeen Proving Ground, MD) and were > 98.6% pure as determined by ³¹P-nuclear magnetic resonance spectroscopy. Paraoxon, atropine sulfate and diisopropylfluorophosphate (DFP) were purchased from Sigma Chemicals (St Louis, MO). Pralidoxime chloride (2-PAM) and obidoxime dichloride (OBID) were purchased from Ayerst Laboratories (New York, NY) and Duphar (Amsterdam, Netherlands), respectively. All drugs were USP grade. Drugs and OP compounds were administered as solutions in saline with injection volumes ≤ 1 ml/kg.

OP compound toxicity

Median lethal doses (LD₅₀) were determined from the 24-h mortality of animals receiving OP compounds by

subcutaneous (sc) administration. LD₅₀ values were calculated by probit analysis (Finney 1971) of mortality fractions with at least six doses of each OP compound and ten animals per dose. Significant differences between probit slopes of dose–response curves were identified by a two-sample *t*-test. Differences were considered significant if *P* < 0.05.

Oxime efficacy

Efficacy of oximes against OP compounds was determined from the 24-h mortality of guinea pigs receiving oxime (145 μmol/kg) and atropine (50 μmol/kg) by intramuscular (im) injection 1 min after sc administration of an OP compound. An oxime's efficacy was expressed as a protective ratio, which is the ratio of the OP LD₅₀ in oxime/atropine-treated animals divided by the OP LD₅₀ in untreated animals. Protective ratios were determined using a stage-wise method (Maxwell et al. 1997).

Mathematical modeling

Mathematical models of relationships between in vivo and in vitro variables were analyzed by linear regression and graphed with SigmaPlot 2000. The fraction of total variation explained by each mathematical model was determined from its regression correlation coefficient (*r*) where $r^2 = (\text{explained variation})/(\text{total variation})$.

Results


To compare the in vivo dose–response curves for a variety of highly toxic OP compounds, the mortality dose–response curves for VX, soman, cyclosarin, sarin, tabun, paraoxon and DFP were determined in guinea pigs. The LD₅₀ values and probit slopes characterizing the dose–response curves for these OP compounds are shown in Table 1. Although these OP compounds exhibited LD₅₀ values that varied 439-fold, their probit slopes were steep (9.6–11.3) and were not significantly different.

To compare OP dose–response curves in different species, the mortality dose–response curves for one OP compound, soman, were also determined in mice, rats and rabbits (Fig. 1). For comparison of soman dose–response curves in rodents and non-human primates, Fig. 1 also contains dose–response curves for marmosets and rhesus monkeys taken from Dirnhuber et al. (1979). Although the LD₅₀ values for soman varied 15-fold among these species, the probit slopes of the

Table 1 Comparison of LD₅₀ values and probit slopes for OP compounds in guinea pigs

OP Compound	LD ₅₀ (μg/kg) sc	Probit slope ± SE
VX	9.15 (8.01–10.3)	10.7 ± 2.55
Soman	34.1 (31.0–37.7)	9.62 ± 2.32
Sarin	44.3 (39.0–50.5)	9.95 ± 2.81
Cyclosarin	57.9 (50.3–66.5)	9.81 ± 2.77
Tabun	117 (101–134)	9.53 ± 2.30
Paraoxon	941 (790–1101)	11.3 ± 3.01
DFP	4018 (3,334–4,741)	9.85 ± 2.46


Values in parentheses are 95% confidence intervals

**Fig. 1** Comparison of the mortality dose–response curves for soman in different species. Data for marmoset and rhesus monkey were taken from Dirnhuber et al. (1979)

soman dose–response curves were similar and as steep in these species as the probit slope for soman in guinea pigs presented in Table 1. These observations demonstrated that highly toxic OP compounds produce similar steep probit slopes regardless of the OP compound or the mammalian species in which the toxicity of the OP compounds is determined.

Evaluation of the hypothesis that AChE inhibition is the in vivo mechanism of OP toxicity was examined in Fig. 2 by regression analysis of the relationship between the bimolecular rate constants for OP inhibition of AChE (k_{AChE}) and OP LD₅₀ values in rats. Regression analysis of in vitro and in vivo data taken from Maxwell (1992) showed that $\text{LD}_{50} \propto (k_{\text{AChE}})^{-1/2}$ with $r^2 = 0.93$, which indicated that 93% of the 3,280-fold variation in the acute toxicity of OP compounds was explained by the variation in the ability of these compounds to inhibit AChE.

Since inhibition of AChE was highly correlated with the toxicity of OP compounds, the ability of reactivation of OP-inhibited AChE to correlate with protection against the toxicity of OP compounds was also examined. The efficacy of 2-PAM (145 μmol/kg)

**Fig. 2** Regression analysis of in vitro inhibition of AChE and in vivo toxicity of OP compounds in rats. LD₅₀ values and inhibition rate constants were taken from Maxwell (1992)

and atropine (50 μmol/kg) against VX, sarin and cyclosarin was determined in guinea pigs and expressed as protective ratios (PR) in Table 2. These data were supplemented with comparable oxime efficacy data from a literature review by Dawson (1994) to increase the number of data points for a regression analysis of in vivo oxime efficacy against in vitro oxime reactivation. The supplemental efficacy data were selected on the basis that oxime PR values had to have been determined (1) in guinea pigs, (2) with a dose of atropine (46–50 μmol/kg) comparable to the dose used in the current paper and (3) with oximes for which in vitro AChE reactivation rate constants were available. These criteria resulted in the addition of the supplemental oxime PR data shown in Table 2 from Fleisher et al. (1970), Lundy et al. (1992) and Inns and Leadbeater (1983). In vitro oxime reactivation constants (k_{R}) were taken from Worek et al. (2002), which contained an extensive study of oxime reactivation of OP-inhibited AChE from guinea pigs.

A regression analysis of the relationship between the in vivo PR of OBID and 2-PAM at different oxime doses and their in vitro k_{R} values for oxime reactivation of OP-inhibited AChE is shown in Fig. 3. Efficacy of oximes against the toxicity of VX, sarin and cyclosarin in guinea pigs was expressed as PR-1, because a PR of 1 denotes an absence of oxime protection, and k_{R} was multiplied by the administered dose of oxime ([Oxime]) to normalize the effect of different oxime doses. Regression analysis showed that $\text{PR}-1 \propto (k_{\text{R}}[\text{Oxime}])^{0.56}$ with $r^2 = 0.91$, which indicated that the ability to reactivate OP-inhibited AChE explained 91% of the 23-fold variation in the efficacy of oximes against highly toxic OP compounds.

Table 2 Comparison of oxime efficacy against OP compounds in guinea pigs

OP Compound	Oxime	Oxime dose ($\mu\text{mol/kg}$)	Protective ratio (PR)	Reference for PR
VX	2-PAM	145	36.8 (27.9–46.1)	Current paper
Sarin	2-PAM	145	22.7 (17.4–29.5)	Current paper
Cyclosarin	2-PAM	145	2.6 (2.1–3.5)	Current paper
VX	2-PAM	130	25	Inns and Leadbeater (1983)
VX	OBID	40	58	Inns and Leadbeater (1983)
Sarin	2-PAM	130	38	Inns and Leadbeater (1983)
Sarin	OBID	40	59	Inns and Leadbeater (1983)
Sarin	2-PAM	43	19	Fleisher et al. (1970)
Sarin	OBID	47	42	Fleisher et al. (1970)
Cyclosarin	OBID	56	4	Lundy et al. (1992)

Values in parentheses are 95% confidence intervals

Discussion

In as much as OP inhibition of AChE *in vitro* is an extremely rapid and specific reaction (De Jong and Benschop 1988), it would be expected that the *in vivo* dose–response of an OP compound would reflect this specificity. Mortality dose–response curves for a variety of highly toxic OP compounds with sc LD_{50} values that varied 439-fold in guinea pigs exhibited similar steep probit slopes that were > 9.6 . Similar monophasic steep probit slopes were also observed when the mortality dose–response curves for soman were examined in six different species whose soman LD_{50} values varied 15-fold. The consistently steep slopes of these OP dose–response curves regardless of their midpoints (i.e., LD_{50}) suggested that OP compounds are potent toxicants for which small changes in dose result in large changes in response.

Compounds with multiple mechanisms of toxicity have complex *in vivo* dose–response curves with

shallow probit slopes that reflect the cumulative effect of multiple toxic mechanisms with different thresholds (Faustman and Omenn 2001). The slopes of the mortality dose–response curves for the highly toxic OP compounds in the current study were similar to the steep slope of the mortality dose–response curve for botulinum toxin (Rai and Van Ryzin 1981), an extremely toxic substance (i.e., $\text{LD}_{50} < 0.01 \mu\text{g/kg}$) with a specific mechanism of toxicity (Szinicz and Baskin 1999). Our analysis of the *in vivo* dose–response curves of highly toxic OP compounds suggested that these compounds have a single specific mechanism of acute *in vivo* toxicity regardless of the OP compound or the species in which OP toxicity is evaluated.

Evaluation of the hypothesis that AChE inhibition is the *in vivo* mechanism of action of OP compounds was examined by two approaches. One approach examined the mathematical relationship between *in vivo* OP LD_{50} values and *in vitro* OP inhibition of AChE (k_{AChE}). Regression analysis of this relationship indicated that 93% of the variation in the acute toxicity of OP compounds was explained by the variation in their ability to inhibit AChE. The other approach was to examine the mathematical relationship between *in vivo* oxime efficacy against OP compounds and *in vitro* oxime reactivation of OP-inhibited AChE. Regression analysis of this relationship indicated that 91% of the variation in the protection of oximes against highly toxic OP compounds was explained by the ability of oximes to reactivate OP-inhibited AChE. The consistency between the ability of AChE inhibition to explain $> 90\%$ of the variation in toxicity of OP compounds and the ability of AChE reactivation to explain $> 90\%$ of the variation in oxime efficacy against OP toxicity presents a compelling argument that AChE inhibition is the primary mechanism of OP toxicity.




Fig. 3 Regression analysis of *in vitro* oxime reactivation and *in vivo* oxime protection in guinea pigs. PR values were taken from Table 2. Reactivation rate constants were taken from Worek et al. (2002)

The best explanation for this variety of observations was that the primary mechanism of *in vivo* toxicity for highly toxic OP compounds is the inhibition of AChE, and the residual unexplained variation in OP toxicity that might be explained by other mechanisms represents < 10% of the total variation across a 3,280-fold range of OP toxicity.

References

- Casida JE, Quistad GB (2005) Serine hydrolase targets of organophosphorus toxicants. *Chem Biol Interact* 157–158:277–283
- Dawson RM (1994) Review of oximes available for treatment of nerve agent poisoning. *J Appl Toxicol* 14:317–331
- De Jong LPA, Benschop HP (1988) Biochemical and toxicological implications of chirality in anticholinesterase organophosphates. In: Ariens EJJ, Van Rensen JS, Welling W (eds) *Stereoselectivity of pesticides: biological and chemical problems*. Elsevier, Amsterdam, pp 109–149
- Dirnhuber P, French MC, Green DM, Leadbeater L, Stratton JA (1979) The protection of primates against soman poisoning by pretreatment with pyridostigmine. *J Pharm Pharmacol* 31:295–299
- Faustman EM, Omenn GS (2001) Risk assessment. In: Klassen CD (ed) *Casarett and Doull's Toxicology: the basic science of poisons*. McGraw-Hill, New York, pp 83–104
- Finney DJ (1971) *Probit analysis*. Cambridge University Press, Cambridge, pp 50–124
- Fleisher JH, Harris LA, Miller GR, Thomas NC, Cliff WC (1970) Antagonism of sarin poisoning in rats and guinea pigs by atropine, oximes and mecamylamine. *Toxicol Appl Pharmacol* 16:40–47
- Inns RH, Leadbeater L (1983) The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guinea pig. *J Pharm Pharmacol* 35:427–433
- Karczmar AG (1970) History of the research with anticholinesterase agents. In: Karczmar AG (ed) *Anticholinesterase agents*, vol. 1, International encyclopedia of pharmacology and therapeutics, Sect 13, Pergamon, Oxford, pp 1–44
- Lundy PM, Hansen AS, Hand BT, Boulet CA (1992) Comparison of several oximes against poisoning by soman, tabun and GF. *Toxicology* 72:99–105
- Marrs TC (1993) Organophosphate poisoning. *Pharmacol Ther* 58: 51–66
- Maxwell D (1992) The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds. *Toxicol Appl Pharmacol* 114:306–312
- Maxwell D, Brecht KM, Koplovitz I (1997) Characterization and treatment of the toxicity of *O*-isobutyl S-[2-(diethylamino)ethyl]methylphosphonothioate, a structural isomer of VX, in guinea pigs. *J Am Coll Toxicol* 15(2):S78–S88
- Pope CN (1999) Organophosphorus pesticides: do they all have the same mechanism of toxicity? *J Toxicol Environ Health B Crit Rev* 2:161–181
- Pope C, Liu J (2004) Non-cholinesterase actions of anticholinesterases. In: Flora SJS, Romano JA, Baskin SI, Sekhar K (eds) *Pharmacological perspectives of toxic chemicals and their antidotes*. Narosa Publishing, New Delhi, pp 215–239
- Rai K, Van Ryzin J (1981) A generalized multihit dose–response model for low-dose extrapolation. *Biometrics* 37:341–352
- Schuh RA, Lein PJ, Beckles RA, Jett DA (2002) Noncholinesterase mechanisms of chlorpyrifos neurotoxicity: altered phosphorylation of Ca²⁺/cAMP response element binding protein in cultured neurons. *Toxicol Appl Pharmacol* 182:176–185
- Sultatos LG (1994) Mammalian toxicology of organophosphate pesticides. *J Toxicol Environ Health* 43:271–289
- Szinicz L, Baskin SI (1999) Chemical and biological agents. In: Marquardt H, Schafer SG, McClellan RO, Welsch F (eds) *Toxicology*. Academic, San Diego, pp 851–877
- Taylor P (2001) Anticholinesterase agents. In: Hardman JG, Limbird LE, Gilman AG (eds) *Goodman and Gilman's Pharmacological basis of therapeutics*. McGraw-Hill, New York, pp 175–191
- Worek F, Reiter G, Eyer P, Szinicz L (2002) Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. *Arch Toxicol* 76:523–529